Your browser doesn't support javascript.
loading
Update on the management of overactive bladder.
Fontaine, Christina; Papworth, Emma; Pascoe, John; Hashim, Hashim.
Afiliação
  • Fontaine C; Specialist Registrar in Urology, University Hospitals Plymouth, Derriford Road, Devon, PL6 8AU, UK.
  • Papworth E; Bristol Urological Institute, Southmead Hospital, Bristol, Somerset, UK.
  • Pascoe J; University Hospitals Plymouth, Devon, UK.
  • Hashim H; Bristol Urological Institute, Southmead Hospital, Bristol, Somerset, UK.
Ther Adv Urol ; 13: 17562872211039034, 2021.
Article em En | MEDLINE | ID: mdl-34484427
ABSTRACT
Overactive bladder (OAB) syndrome is a common condition characterised by urinary urgency, with or without urgency incontinence, frequency and nocturia, in the absence of any other pathology. Clinical diagnosis is based upon patient self-reported symptomology. Currently there is a plethora of treatments available for the management of OAB. Clinical guidelines suggest treatment via a multidisciplinary pathway including behavioural therapy and pharmacotherapy, which can be commenced in primary care, with referral to specialist services in those patients refractory to these treatments. Intradetrusor botulinum A and sacral neuromodulation provide safe and efficacious management of refractory OAB. Percutaneous tibial nerve stimulation and augmentation cystoplasty remain available and efficacious in a select group of patients. Unfortunately, there remains a high rate of patient dissatisfaction and discontinuation in all treatments and thus there remains a need for emerging therapies in the management of OAB.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Ther Adv Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Ther Adv Urol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido